Bain Capital is exploring a sale of Centrient Pharmaceuticals, an antibodies manufacturer that could be valued at as much as €1 billion ($1.1 billion), people familiar with the matter said.
The private equity firm is working with Citigroup Inc. and Jefferies Financial Group Inc. on a possible divestment of Netherlands-based Centrient, according to the people, who asked not to be identified discussing confidential information.
Deliberations are ongoing and there’s no certainty they will result in a sale, the people said. Representatives for Bain, Citigroup and Jefferies declined to comment.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
Bain acquired Centrient, which was previously called DSM Sinochem Pharmaceuticals, in 2018. Centrient makes intermediates and active pharmaceutical ingredients, as well as tablets, capsules and other finished dosage forms, according to its website.
Bankers are expecting an increase in private equity exits this year, with buyout firms under pressure to return cash to investors after a prolonged period of inactivity.
Source:BNNBloomberg
Can’t stop reading? Read more
J.P. Morgan closes $1.44bn flagship private equity fund above target
J.P. Morgan closes $1.44bn flagship private equity fund above target J.P. Morgan Asset...
Levine Leichtman backs USA Industries in new lower mid-market platform deal
Levine Leichtman backs USA Industries in new lower mid-market platform deal Levine Leichtman...
KKR backs Premialab in $220m push into Middle East growth technology
KKR backs Premialab in $220m push into Middle East growth technology KKR has agreed to invest...